InMed Pharmaceuticals: Funding, Investors & Team (Sep 2026)
A leader in the creation, production, and marketing of rare cannabinoids is InMed Pharmaceuticals. We have unmatched cannabinoid production capabilities with our subsidiary, BayMedica, to service a variety of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage startup focused on providing patients with additional therapy options that may complement marijuana-based pharmaceutical medications. It is creating a pipeline of uncommon cannabinoid treatments. Visit www.inmedpharma.com for more details. Exchange: INM
InMed Pharmaceuticals has raised $12.0M across 2 funding rounds on record, the most recent an undisclosed round of $6.0M announced in Nov 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
InMed Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Nov 2022.
InMed Pharmaceuticals Funding Rounds
InMed Pharmaceuticals raised $6.0M in a Post-IPO Equity announced in Sep 2022.
2 months later, an undisclosed round of $6.0M was announced in Nov 2022.
InMed Pharmaceuticals Founders and Leadership Team
Contact details for the InMed Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →InMed Pharmaceuticals Funding Compared to Other Biotechnology Startups
InMed Pharmaceuticals' latest round of $6.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like InMed Pharmaceuticals in Biotechnology and Vancouver
Companies Similar to InMed Pharmaceuticals
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
InMed Pharmaceuticals Funding FAQs
What does InMed Pharmaceuticals do?
A leader in the creation, production, and marketing of rare cannabinoids is InMed Pharmaceuticals. We have unmatched cannabinoid production capabilities with our subsidiary, BayMedica, to service a variety of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage startup focused on providing patients with additional therapy options that may complement marijuana-based pharmaceutical medications. It is creating a pipeline of uncommon cannabinoid treatments. Visit www.inmedpharma.com for more details. Exchange: INM
How much funding has InMed Pharmaceuticals raised?
InMed Pharmaceuticals has raised $12.0M across 2 rounds on record. The most recent is an undisclosed round of $6.0M announced in Nov 2022.
When did InMed Pharmaceuticals last raise funding?
InMed Pharmaceuticals' most recent funding round on record is an undisclosed round of $6.0M, announced in Nov 2022.
Who is the CEO of InMed Pharmaceuticals?
Eric Adams is listed as CEO at InMed Pharmaceuticals.
Where is InMed Pharmaceuticals headquartered?
InMed Pharmaceuticals is based in Vancouver, British Columbia, Canada.
How many employees does InMed Pharmaceuticals have?
InMed Pharmaceuticals is in the 11-50 employee band.
How does InMed Pharmaceuticals' funding compare to other Biotechnology startups?
InMed Pharmaceuticals' latest round of $6.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's InMed Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for InMed Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.